Evidence map›Paper›PMID 40879695›Full record

Observational studyEuropean radiology2026

One-year outcomes of glue prostate-artery-embolization for symptomatic benign prostatic hyperplasia: a single-center retrospective cohort study.

Romaric Loffroy, Alexis Quirantes, Makoto Taninokuchi Tomassoni, Mohamed Fouad, Pierre-Olivier Comby, Ludwig Serge Aho-Glélé, Olivier Chevallier

Abstract readObservational Study
PubMed Publisher
In one paragraph

Observational study in European radiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Review
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Romaric LoffroyDepartment of Vascular and Interventional Radiology, Image-Guided Therapy Center, François-Mitterrand University Hospital, Dijon, France. romaric.loffroy@chu-dijon.fr.ORCID http://orcid.org/0000-0002-3107-5967
Alexis QuirantesDepartment of Vascular and Interventional Radiology, Image-Guided Therapy Center, François-Mitterrand University Hospital, Dijon, France.
Makoto Taninokuchi TomassoniDepartment of Vascular and Interventional Radiology, Image-Guided Therapy Center, François-Mitterrand University Hospital, Dijon, France.
Mohamed FouadDepartment of Vascular and Interventional Radiology, Image-Guided Therapy Center, François-Mitterrand University Hospital, Dijon, France.
Pierre-Olivier CombyICMUB Laboratory, UMR CNRS 6302, University of Burgundy, Dijon, France.
Ludwig Serge Aho-GléléDepartment of Epidemiology, Statistics and Clinical Research, François-Mitterrand University Hospital, Dijon, France.
Olivier ChevallierDepartment of Vascular and Interventional Radiology, Image-Guided Therapy Center, François-Mitterrand University Hospital, Dijon, France.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesTo assess 12-month outcomes of prostate artery embolization (PAE) using N-butyl cyanoacrylate (NBCA) glue in patients with incapacitating lower-urinary-tract symptoms (LUTS) due to benign prostatic hyperplasia (BPH). MATERIALS AND

methodsRetrospective single-center observational study of patients evaluated 12 months after PAE done in 2018-2023 using methacryloxysulfolane-NBCA mixed with ethiodized oil. Glue injection was under free- or blocked-flow conditions, depending on artery size and real-time assessment of penetration. Both distal embolization and proximal prostatic-artery occlusion were achieved without filling of collaterals. The 12-month outcomes were the International Prostate Symptom Score (IPSS) and associated Quality-of-Life score (IPSS-QoL), prostate volume, International Index of Erectile Function form 5 (IIEF5), and prostate-specific antigen (PSA) level.

resultsA total of 186 patients with a mean age of 67.5 ± 6.0 years were included. All procedures were technically successful. Minor adverse events occurred in 35/186 (18.8%) patients. There were no major complications. At 12 months, significant improvements vs baseline were noted for the IPSS (10 ± 6.6 vs 20.1 ± 6.4, p = 0.0001), IPSS-QoL (2.2 ± 1.6 vs 5.1 ± 0.9, p = 0.0001), and prostate volume (81.1 ± 47.0 mL vs 118.1 ± 67.4 mL, p = 0.0001). The IIEF5 and PSA levels were not significantly different at 12 months vs baseline (16.2 ± 7.2 vs 15.8 ± 6.9, p = 0.814; and 4.9 ± 3.3 vs 4.8 ± 4.2, p = 0.286; respectively).

conclusionsOur data support the feasibility, safety, and sustained effectiveness at 12 months of PAE with NBCA to treat BPH-related LUTS. KEY POINTS: Question NBCA glue may have advantages over other agents for prostatic artery embolization in BPH, but data on long-term outcomes are scarce. Findings Prostatic artery embolization using glue led to significant decreases in the International Prostate Symptoms Score, quality of life score, and prostate volume at 12-month follow-up. Clinical relevance NBCA glue for prostatic artery embolization in patients with symptomatic BPH is safe and provides sustained symptom relief for at least one year.

Indexed as

Embolization, TherapeuticEnbucrilateLower Urinary Tract SymptomsProstateProstatic HyperplasiaAgedHumansMaleMiddle AgedQuality of LifeRetrospective StudiesTreatment OutcomeEnbucrilateBenign prostatic hyperplasiaCyanoacrylatesLower urinary tract symptomsProstatic artery embolization

Identifiers

PMID40879695

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.